DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2241560/pagerduty-pd-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2241560 Mar 15, 2024 - PagerDuty's (PD) fourth-quarter fiscal 2024 results benefit from an expanding customer base. 0

https://www.zacks.com/stock/news/2241032/pagerduty-pd-q4-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2241032 Mar 14, 2024 - PagerDuty (PD) delivered earnings and revenue surprises of 13.33% and 0.56%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://seekingalpha.com/article/4662621-pds-biotechnology-promising-phase-2-cash-issues-worth-risk?source=feed_all_articles Jan 12, 2024 - PDS Biotech, a clinical-stage company specializing in immunotherapy for cancer, with a focus on virus-driven tumors and promising clinical data. Read more here. 0

https://www.zacks.com/stock/news/2204567/all-you-need-to-know-about-pds-biotechnology-pdsb-rating-upgrade-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2204567 Jan 02, 2024 - PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 0

https://www.zacks.com/stock/news/2195686/earnings-estimates-rising-for-pagerduty-pd-will-it-gain?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-2195686 Dec 08, 2023 - PagerDuty (PD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. 0

https://www.zacks.com/stock/news/2192455/pagerduty-pd-q3-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2192455 Dec 01, 2023 - PagerDuty's (PD) third-quarter fiscal 2024 results benefit from an expanding customer base. 0

https://seekingalpha.com/article/4655307-pagerduty-inc-pd-q3-2024-earnings-call-transcript?source=feed_sector_transcripts Nov 30, 2023 - 0